Jagsonpal Pharmaceuticals has fixed Friday, September 04, 2026, as the record date for determining member entitlement to the dividend for the financial year ended March 31, 2026. This action follows the Board of Directors' recommendation on April 27, 2026, of a dividend of Rs 4 per equity share, which translates to a 200% payout on the face value of Rs 2. The declaration is subject to final approval by shareholders at the company's 47th Annual General Meeting (AGM).

The AGM is scheduled to be held on Friday, September 18, 2026, at 03:30 p.m. (IST). In compliance with circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (SEBI), the meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM). Shareholders holding equity shares on the specified record date will be eligible to receive the dividend if the resolution passes.

Dividend Details

The following table outlines the key parameters of the proposed dividend distribution:

Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Jagsonpal Pharmaceuticals issued this intimation to the BSE Ltd and the National Stock Exchange of India Ltd. The company stated that the dividend, once approved by members at the AGM, will be paid within 30 days from the date of its declaration. Payments will be subject to the deduction of applicable taxes at source.

What the Numbers Show

The proposed dividend represents a significant return to shareholders, with the payout amounting to twice the face value of the equity shares. This high payout ratio suggests strong liquidity or retained earnings position for the firm in FY26. The separation of the record date (September 04) from the AGM date (September 18) provides a clear window for trade settlement, ensuring that investors who acquire shares before the record date are eligible for the distribution, provided the Board's recommendation is ratified by the general body of shareholders.

Jagsonpal Pharmaceuticals reported a 22.2% year-on-year increase in standalone net profit to ₹132 million for the quarter ended June 30, 2026 (Q1FY27), driven by an 8.8% rise in revenue from operations to ₹822 million. Operating EBITDA grew 21.4% to ₹191 million, expanding the margin to 23.2% from 20.8% in the prior year period. The strong financial performance was underpinned by improved medical representative productivity and higher sales across key brands, allowing the company to outperform the industry average of 11.6% growth recorded by Pharmarack for the Indian pharmaceutical market. These results were approved by the Board of Directors on July 29, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company’s cash reserves remained robust at ₹1,700 million despite concluding a ₹400 million share buyback and completing the acquisition of an 85% stake in Aequitas Healthcare Private Limited for ₹208 million. Management highlighted that the disciplined capital allocation has resulted in a return on capital employed (ROCE) improvement of 340 basis points. Manish Gupta, Managing Director and CEO, stated that the quarter reflected sustained traction with revenue growing 9% YoY, driven by higher MR productivity. He noted that Jagsonpal significantly outperformed the industry, improving its rank to #88 in the Indian pharmaceutical market.

Financial Highlights

The table below presents a summary of key financial metrics for the quarter, reflecting broad-based improvement across revenue, profitability, and operational efficiency.

*Operating EBITDA and EBITDA margins are calculated before Employee Stock Option Plan (ESOP) costs.

Revenue from operations increased by ₹66 million compared to the same period last year. Gross profit rose to ₹536 million from ₹487 million, with gross margin expanding to 65.2% from 64.4%. Total expenses were ₹632 million, up 5.4% year-on-year, demonstrating significant operating leverage as expense growth lagged revenue growth.

Strategic Developments

During the quarter, Jagsonpal Pharmaceuticals completed the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited for ₹208 million, funded through internal accruals. This transaction marks the company’s entry into the hospital supplies segment, providing immediate access to over 1,000 hospitals and relationships with more than 4,000 doctors. Aequitas reported FY26 revenue of ₹533 million. Management targets generating approximately ₹100 million in EBITDA by Year 2 post-integration through cross-selling Jagsonpal’s portfolio across these hospital channels and consolidating supply chains.

Additionally, the company concluded its buy-back of up to 1,600,000 equity shares at ₹250 per share, with an aggregate consideration not exceeding ₹400 million. Under the Employee Stock Option Plan 2022, the company granted 153,000 stock options and allotted 473,220 equity shares upon exercise of vested options during the quarter.

What the Numbers Show

The divergence between revenue growth (8.8%) and total expense growth (5.4%) indicates improved operating leverage for Jagsonpal Pharmaceuticals in Q1FY27. The expansion of Operating EBITDA margin to 23.2% from 20.8% underscores strengthening core operational profitability, driven by enhanced medical representative productivity. This efficiency gain directly contributed to the 22.5% surge in profit before tax. The completion of the Aequitas acquisition positions the company for future scale in the institutional channel, while the retention of a ₹1,700 million cash balance despite significant capital deployment highlights the strength of its asset-light business model and free cash flow generation capabilities.